HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area-purity target on each production lot.
Pepti · Catalog · Cagrilintide
GLP-1 family · research-use
Lyophilized cagrilintide (long-acting amylin analog research compound) for research labs and private-label brand evaluation worldwide. ≥99% HPLC purity target, batch-linked COA, HPLC chromatogram and MS identity record.
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework, with public comment open through 2026-06-29. Pending finalization, this compound is positioned for research and private-label brand evaluation worldwide. Read the GLP-1 2026 update →
Vial illustrations reflect supplied lyophilized format. Lot codes are sample identifiers; production lots carry their own batch references.
| Compound | Cagrilintide |
|---|---|
| CAS number | 1415456-99-3 |
| Class | Long-acting amylin analog (research) |
| Molecular weight | Confirmed on batch-linked COA for each production lot |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg, 10 mg (custom on request) |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | 2–8 °C protected from light; long-term −20 °C |
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
Cagrilintide is most often quoted alongside semaglutide in research stacks. All quotes require a destination country and buyer track.
Documentation
COA, HPLC chromatogram, MS identity confirmation, water content and storage notes. Buyer track and destination confirmed before invoicing.
Reverse-phase HPLC with UV detection; ≥99% area-purity target on each production lot.
Mass spectrometry identity confirmation against the Cagrilintide reference profile.
Lot code printed on vial label and reflected in the document pack. Reorders cite the prior lot for continuity.
FAQ
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. While cagrilintide is an amylin analog, Pepti supplies it as a research peptide worldwide; buyers confirm local compliance.
Yes — the amylin + GLP-1 stack is a common research / private-label evaluation pair. Both can be quoted together in the Quote Cart.
Latin America, Southeast Asia, parts of the Middle East, and select EMEA distributors with appropriate local registration.
Sample lots from 100 vials; production lots from 500 vials with tier pricing.
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability.
Related compounds